Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03066648 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03066648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03066648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
July 6, 2017
Completion date
September 8, 2023
Enrollment
241 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow diseases, chronic myelomonocytic leukemia, hematologic diseases, leukemia, leukemia, myeloid, leukemia, myeloid, acute, myelodysplastic syndromes, preleukemia